Full-Time

Associate Director

Accounting

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$183k - $194kAnnually

+ Equity Component + Comprehensive Benefits

Expert

San Carlos, CA, USA

Hybrid position requiring onsite work 3 days per week.

Category
Financial Accounting
Financial Controller
Management Accounting
Accounting
Required Skills
NetSuite
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

You match the following Vaxcyte's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree in Finance/ Accounting or equivalent is required; C.P.A and experience at in public accounting, is preferred.
  • 10+ years of experience accounting operations with progressive levels of responsibility is required.
  • 4+ years of experience supervising, planning and directing the work of multiple direct reports is required.
  • Experience in accounting roles with varying degrees of complexity.
  • Superior computer skills (Microsoft Office including Excel, Word and PowerPoint).
  • NetSuite experience a plus.
  • Experience with Netsuite, ADP, SAP Concur and other accounting and reporting tools is a plus.
  • Excellent oral and written communication skills.
  • Strong problem-solving skills.
  • Excellent attention to details.
  • Self-motivated and self-directed.
  • Public company experience is preferred.
  • Ability to work onsite 3 days per week required; and more often based on business needs.
Responsibilities
  • Supervising a team of at least two (2) direct reports, primarily leading accounting operations and/or shared services that support the business.
  • Lead functions under management in identifying, reviewing/verifying, analysis and implementing process improvement opportunities including impact and risk assessments, status reporting and change management.
  • Ensure proper reviews and issues are resolved timely, that our processes are compliant with established SOX controls and that we ascertain the accuracy and completeness of the underlying transactions.
  • Collaborates well with the extended finance team to ensure adherence to a timely close and reporting process, timely responses to internal/external audit requests and overall execution of team objectives.
  • Involvement in special projects, system implementations, upgrades, integrations or process improvements, as needed.
  • Develop and manage a high functioning, efficient and responsive team.
  • Own accruals for certain vendors, including management of accrual, review of open purchase orders and invoices, and review of reconciliations and latest estimate processes.
  • Collaborate closely with internal and external teams, as well as FP&A to understand scope to inform the accrual process and report accurately and timely.
Desired Qualifications
  • C.P.A and experience at in public accounting, is preferred.
  • NetSuite experience a plus.
  • Experience with Netsuite, ADP, SAP Concur and other accounting and reporting tools is a plus.
  • Public company experience is preferred.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Size

201-500

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
MarketBeat
Oct 5th, 2024
Clearbridge Investments LLC Makes New $14.06 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).

Bizjournals
Sep 20th, 2024
Winner, Public Company, Small: Andrew Guggenhime, Vaxcyte Inc.

In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.

Yahoo Finance
Sep 9th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock

Vaxcyte
Sep 6th, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte announces closing of $1.5 billion public offering including full exercise of underwriters' option to purchase additional shares.

GlobeNewswire
Sep 5th, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte announces pricing of $1.3 billion public offering.